Trials / Recruiting
RecruitingNCT07059767
Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge
A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Ethris GmbH · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ETH47 | single intranasal dose of ETH47 |
| DRUG | Placebo | single intranasal dose of placebo |
Timeline
- Start date
- 2025-06-24
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2025-07-11
- Last updated
- 2025-08-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07059767. Inclusion in this directory is not an endorsement.